ABOS 2.86 Acumen Pharmaceuticals, Inc.
| Range: | 1.81-5.09 | Vol Avg: | 220290 | Last Div: | 0 | Changes: | 0.2 |
| Beta: | 0.07 | Cap: | 0.17B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Jul 01 2021 | Empoloyees: | 51 | ||
| CUSIP: | 00509G209 | CIK: | 0001576885 | ISIN: | US00509G2093 | Country: | US |
| CEO: | Mr. Daniel J. O'Connell M.B.A. | Website: | https://acumenpharm.com | ||||
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Stock Details
ABOS 7
Acumen initiated with a Buy at Citi
David Hoang·Thu Jul 25 2024
Citigroup
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow